$25 Million

Ocera Therapeutics

At-the-market Offering

Developer of novel therapeutics designed to treat acute and chronic liver diseases. The company's novel therapeutics portfolio consists of OCR-002, an ammonia scavenger used in both intravenous (IV) and oral formulations for the treatment of hyperammonemia and STOP-HE, enabling physicians to receive biopharmaceuticals that helps in resolving neurocognitive symptoms of acute HE.